Warfarin
Warfarin: Pharmacogenomics and Public Health - July 1, 2015
Medicare National Coverage Determinations
Baltimore (MD):Centers for Medicare & Medicaid Services (US) 2009
Baltimore (MD):Centers for Medicare & Medicaid Services (US) 2009
Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.
Santos PC et al. Pharmacogenomics 2015 Jun 8. 1-12
Santos PC et al. Pharmacogenomics 2015 Jun 8. 1-12
Warfarin: What is it and why is it used? MedlinePlus, National Library of Medicine
MedlinePlus, National Library of MedicineGenetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Jessica Mega et al. Lancet, March 10, 2015
Jessica Mega et al. Lancet, March 10, 2015
Dosing guideline for warfarin and CYP2C9, VKORC1, Clinical Pharmacogenomics Implementation Consortium 2014
Clinical Pharmacogenomics Implementation Consortium 2014How many genes have been reported to be associated with warfarin efficacy and side effects?From the HuGE Navigator
From the HuGE NavigatorImpact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan Manal F et al. Blood Coagul. Fibrinolysis 2015 Feb 19.
Ghozlan Manal F et al. Blood Coagul. Fibrinolysis 2015 Feb 19.
Oral anticoagulation: a critique of recent advances and controversies.
Pirmohamed Munir et al. Trends Pharmacol. Sci. 2015 Mar (3) 153-163
Pirmohamed Munir et al. Trends Pharmacol. Sci. 2015 Mar (3) 153-163
PGWD: integrating personal genome for warfarin dosing.
Pan Yidan et al. Interdiscip Sci 2015 Feb 6.
Pan Yidan et al. Interdiscip Sci 2015 Feb 6.
Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.
Rubio-Terrés C et al. Appl Health Econ Health Policy 2015 Feb 5.
Rubio-Terrés C et al. Appl Health Econ Health Policy 2015 Feb 5.
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
Chang Ming et al. Eur. J. Clin. Pharmacol. 2015 Feb 6.
Chang Ming et al. Eur. J. Clin. Pharmacol. 2015 Feb 6.
Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova Ekaterina V et al. Expert Opin Drug Metab Toxicol 2015 Jan 16. 1-14
Baranova Ekaterina V et al. Expert Opin Drug Metab Toxicol 2015 Jan 16. 1-14
Genotype and risk of major bleeding during warfarin treatment.
Kawai Vivian K et al. Pharmacogenomics 2014 Dec (16) 1973-83
Kawai Vivian K et al. Pharmacogenomics 2014 Dec (16) 1973-83
Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.
Hernandez Wenndy et al. Transl Res 2014 Nov 22.
Hernandez Wenndy et al. Transl Res 2014 Nov 22.
Warfarin pharmacogenetics.
Johnson Julie A et al. Trends Cardiovasc. Med. 2015 Jan (1) 33-41
Johnson Julie A et al. Trends Cardiovasc. Med. 2015 Jan (1) 33-41
Warfarin pharmacogenomics: recommendations with available patented clinical technologies.
Borkowski Andrew A et al. Recent Pat Biotechnol 2014 (2) 110-5
Borkowski Andrew A et al. Recent Pat Biotechnol 2014 (2) 110-5
The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?
Baranova E V et al. Curr. Mol. Med. 2014 (7) 841-8
Baranova E V et al. Curr. Mol. Med. 2014 (7) 841-8
Genotype-guided drug prescribing: A systematic review and meta-analysis of randomized control trials.
Goulding Rebecca et al. Br J Clin Pharmacol 2014 Jul 24.
Goulding Rebecca et al. Br J Clin Pharmacol 2014 Jul 24.
.png)
No hay comentarios:
Publicar un comentario